Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study

Gian Battista Fausto Bolis, G Scarfone, F Raspagliesi, G Mangili, S Danese, P Scollo, D Lo Russo, A Villa, Pd Aimone, Giovanni Scambia

Risultato della ricerca: Contributo in rivistaArticolo in rivista

36 Citazioni (Scopus)

Abstract

The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.
Lingua originaleEnglish
pagine (da-a)2905-2912
Numero di pagine8
RivistaEuropean journal of cancer (Oxford, England : 1990)
Volume46
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Ovarian Neoplasms
  • Paclitaxel
  • Topotecan
  • Treatment Outcome
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study'. Insieme formano una fingerprint unica.

Cita questo